[1] 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J].中华消化杂志,2017,37(8):513-522.
[2] Kawanami Y,Kitazawa R,Haraguchi R,et al.Hepatic sinusoidal obstruction syndrome without preceding medical events[J].CRCM,2016,5:105-108.
[3] Wang Y, Qiao D, Li Y, et al.Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study[J]. BMC Gastroenterol,2018,18(1):156.
[4] Richardson P G, Grupp S A, Pagliuca A, et al.Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure[J].Int J Hematol Oncol,2017,6(3):75-93.
[5] Stuart K L, Bras G. Veno-occlusive disease of the liver[J]. Q J Med,1957,26(103):291-315.
[6] Hill K P,Rhodes K,Stafford J L,et al.Serious hepatosis:a pathogenesis of hepatic fibrosis in Jamaican children[J],Br Med J,1953,1(4802):117-122.
[7] Bras G, HILL K R.Veno-occlusive disease of the liver essential pathology[J]. Lancet, 1956,271(6935):161-163.
[8] DeLeve L D, Shulman H M, McDonald G B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)[J]. Semin Liver Dis, 2002,22(1):27-42.
[9] Dusemund B, Nowak N, Sommerfeld C,et al. Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin[J].Food Chem Toxicol,2018,115:63-72.
[10] Nishida M, Kahata K, Hayase E, et al. Novel ultrasonographic scoring system of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant,2018,24(9):1896-1900.
[11] Takeuchi M, Oda S, Tsuneyama K, et al.Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS[J].Arch Toxicol, 2018 ,92(9):2947-2962.
[12] Tavernier E, Chalayer E, Cornillon J, et al.Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report[J].BMC Res Notes,2018,11(1):436.
[13] Pihusch M, Wegner H, Goehring P, et al. Diagnosis of hepatic venoocclusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients[J]. Transplantation,2005,80:1376-1382.
[14] Matsukuma S, Takeo H, Utsumi Y, et al. In hepatic venous outflow obstruction, alcoholic liver disease, and nonalcoholic fatty liver disease, centrilobular scars, CD34+ vessels, and keratin 7+ hepatocytes are in close proximity[J]. Virchows Arch,2017,470(4):411-420.
[15] McConnell M, Iwakiri Y.Biology of portal hypertension[J].Hepatol Int,2018,12(1):11-23.
[16] Dalle J H,Giralt S A.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment[J]. Biol Blood Marrow Transplant,2016,22(3):400-409.
[17] Myers K C, Dandoy C, El-Bietar J, et al. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplant[J]. Biol Blood Marrow Transplant,2015,21:379-381.
[18] Yang S, Wu J, Lei S.CT Features of hepatic veno-occlusive disease:a meta-analysis[J].Acad Radiol,2018,25(3):328-337.
[19] Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation[J]. Br J Haematol,2015,168:481-491
[20] Li X, Yang X, Xu D, et al.Magnetic resonance imaging findings in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Clin Gastroenterol Hepatol,2017,15(6):955-957.
[21] Tewari P,Wallis W,Kebriaei P. Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies[J]. Clin Adv Hematol Oncol.2017,15(2):130-139.
[22] Nassereddine S, Alsubait S, Tabbara I.Sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic stem cell transplant: insights and therapeutic advances[J].Anticancer Res,2018,38(5):2597-2605.
[23] Dignan F L, Wynn R F, Hadzic N, et al.Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol,2013,163(4):444-457.
[24] Richardson P G, Triplett B M, Ho V T, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Expert Rev Clin Pharmacol, 2018,11(2):113-124.
[25] Lee A C, Aung L.Treatment of hepatic veno-occlusive disease in children with N-acetylcysteine.[J].Pediatr Blood Cancer,2018,23:e27518.
[26] Kernan N A, Richardson P G, Smith A R,et al. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: final results from a post hoc analysis of data from an expanded-access program[J]. Pediatr Blood Cancer,2018,65(10):e27269.
[27] Fan C Q,Crawford J M. Crawford.Sinusoidal obstruction syndrome(Hepatic venular occlusive disease)[J].J Clin Exp Hepatol,2014,4:332-336.
[28] Dominique-CharlesValla,DominiqueCazals-Hatem.Sinusoidal obstruction syndrome[J].Clin Res Hep Gas,2016,40(4):378-385.